Nursing · Independent exam preparation
CNN-NP Nephrology Decision Guide Study Guide
Practise nephrology NP decisions in AKI, CKD progression, prescribing, dialysis access, fluid management, peritonitis and transplant care through cases and explained questions.
By CertMedbry · Updated 27 October 2026
Practise distinguishing reversible kidney injury, selecting kidney-protective treatment, planning kidney failure care and resolving dialysis complications. These 60 selective concepts connect assessment findings to prescribing, patient education and shared decisions across all five CNN-NP domains. The official NNCC outline defines the full examination scope. These independently authored learning materials use clinical guidelines for clinical recommendations and NNCC documents for examination scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
How many questions are there, and how long is the examination?
NNCC's CNN-NP page states 175 questions with four hours to complete the examination. The January 2025 application booklet contains a conflicting development narrative describing 150 questions and approximately 25 unscored pilot questions. These descriptions do not establish an unambiguous scored/pretest split. Confirm appointment-specific examination information with NNCC.
CNN-NP | Nephrology Nursing Certification Commission · CNN-NP Certification Examination Application, revised January 2025
What delivery method and question styles are verified?
NNCC describes computer-based testing, an available calculator and multiple-choice questions with one correct answer among four choices. These descriptions do not establish adaptive delivery. This guide's 20 questions are independent single-best-answer learning drills; their results do not predict certification outcomes.
Which blueprint does this guide follow?
The directly linked blueprint and specifications both say revised May 2013 and effective July 2014. Their weights are Acute Kidney Injury 4–6%; Stages 1 & 2 CKD and General Nephrology 4–6%; Stage 3 CKD 11–13%; Stages 4 & 5 CKD not on KRT 19–21%; and Kidney Replacement Therapies 57–59%. These are historical effective dates, not a newly issued 2026 syllabus.
Ideal Distribution of Questions in CNN-NP Certification Examination · CNN-NP Examination Specifications (Blueprint)
Why do other NNCC documents show different weights?
The preparation guide contains an outline revised April 2018 and implemented July 2019: AKI 6–8%, early CKD/general nephrology 4–6%, stage 3 CKD 11–13%, advanced CKD 20–22% and KRT 54–56%. The January 2025 application reproduces the older outline but gives KRT as 56–59%; the certification page also uses 56–59%. These documents do not resolve which conflicting outline governs an individual appointment. Confirm the applicable outline with NNCC.
CNN-NP Certification Preparation Guide · CNN-NP Certification Examination Application, revised January 2025 · CNN-NP | Nephrology Nursing Certification Commission
How is the material distributed across domains?
Following the directly linked outline approximately, the guide contains 3 AKI, 3 early CKD/general nephrology, 7 stage 3 CKD, 12 advanced CKD and 35 KRT concepts. Both the questions and flashcards contain 1, 1, 2, 4 and 12 items respectively. Rounding and selective coverage prevent exact percentage matching. The linked blueprint gives KRT subdivisions of hemodialysis 82–84, PD 5–7, transplant 8–10 and CRRT 0–2 items.
Ideal Distribution of Questions in CNN-NP Certification Examination
Which nurse practitioner activities does the outline emphasize?
The linked specifications allocate 38–40% to assessment and diagnosis; 43–45% to prescribing interventions, including pharmacology 21–23% and other interventions 21–23%; 8–10% to education resources; 3–5% to interdisciplinary care; and 3–5% to holistic care reflecting individual values and beliefs. Study clinical decisions across these activities rather than memorizing disease labels alone.
Which professional pathway and jurisdiction does CNN-NP address?
The NNCC listing requires a full, unrestricted RN license in the United States or its territories, national NP certification and at least a master's degree in nursing, alongside nephrology experience and continuing education requirements. CNN-NP is the NP pathway selected here. The separate CNN and CDN credentials do not provide interchangeable eligibility or examination content.
This guide addresses NNCC's Certified Nephrology Nurse - Nurse Practitioner (CNN-NP) credential for nephrology nurse practitioners. CNN, CDN and dialysis technician credentials are separate examinations. CNN-NP specialty certification does not replace the national NP certification or jurisdictional authorization required to practise. Older issuer documents use acute renal failure and renal replacement terminology for areas now labeled AKI and KRT; these wording differences do not establish another examination.
Outline used: Verified on 2026-10-11 for Asia/Hong_Kong. The workbook label matches NNCC's official CNN-NP credential. Coverage uses NNCC's currently linked examination blueprint and specifications, explicitly revised May 2013 and effective July 2014; this historical version remains publicly linked and is not presented as a newly issued 2026 syllabus. NNCC's preparation guide also contains a conflicting outline revised April 2018 and implemented July 2019. Both versions and their weights are preserved below.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Acute Kidney Injury4–6%
1.How is acute kidney injury identified and staged?
AKI is present with a serum creatinine rise of at least 0.3 mg/dL within 48 hours, a rise to at least 1.5 times baseline known or presumed to have occurred within seven days, or urine output below 0.5 mL/kg/hour for six hours. Adult staging uses either creatinine or urine output: | Stage | Serum creatinine or KRT criterion | Urine-output criterion | | --- | --- | --- | | 1 | 1.5–1.9 times baseline or an acute increase of at least 0.3 mg/dL | Below 0.5 mL/kg/hour for 6–12 hours | | 2 | 2.0–2.9 times baseline | Below 0.5 mL/kg/hour for at least 12 hours | | 3 | At least 3 times baseline, an acute increase to at least 4.0 mg/dL, or KRT initiation | Below 0.3 mL/kg/hour for at least 24 hours or anuria for at least 12 hours | Apply the highest qualifying stage. Creatinine may lag behind injury, and preserved urine output does not exclude AKI.
Apply it
Creatinine rising from 0.9 to 1.9 mg/dL over four days meets stage 2 criteria despite normal urine volume. If that patient also has anuria for 12 hours, the urine-output criterion raises the classification to stage 3.
Common pitfall: Do not stage from creatinine alone when urine-output criteria indicate greater severity. A chronically elevated creatinine of 4.0 mg/dL does not establish stage 3 AKI without evidence of an acute process.
2.Which findings identify reversible contributors to AKI?
AKI evaluation connects perfusion, urinary obstruction and intrinsic kidney injury to the clinical setting. Review blood pressure, volume losses, medications, infection, urinalysis and urinary tract obstruction risk. Restore perfusion when hypovolemia is present, but assess congestion before administering fluid. Bladder assessment or imaging can identify obstruction. Urine sediment containing cellular casts or substantial blood and protein redirects evaluation toward intrinsic disease rather than uncomplicated volume depletion.
Apply it
An older patient develops oliguria after starting an anticholinergic and reports suprapubic discomfort. A distended bladder makes retention a reversible priority; catheter drainage and assessment of the obstructing cause are more informative than repeated fluid boluses.
Common pitfall: Calling every creatinine rise dehydration can worsen congestion or delay obstruction relief. Urine chemistry indices also lose specificity with diuretics and several intrinsic kidney disorders.
3.Why does apparent AKI recovery require follow-up?
AKI increases subsequent CKD risk even when creatinine improves before discharge. KDIGO recommends evaluation three months after AKI for resolution, new CKD or worsening pre-existing CKD. Follow-up should connect kidney function, albuminuria, blood pressure and medication safety with the original injury. Earlier reassessment is appropriate when recovery is incomplete or electrolyte and volume abnormalities persist. A recovering creatinine trend does not establish stable medication clearance.
Apply it
A patient leaves hospital with creatinine falling from 3.0 to 1.5 mg/dL after sepsis. Arrange early laboratory and medication review, then reassess kidney status around three months instead of declaring recovery from one improving result.
Common pitfall: Stopping surveillance once dialysis is discontinued misses residual dysfunction. The three-month CKD assessment does not justify delaying earlier review of persistent hyperkalemia or incomplete recovery.
Stages 1 & 2 CKD and General Nephrology4–6%
4.What establishes CKD when eGFR is preserved?
CKD requires an abnormality of kidney structure or function present for at least three months with health implications. G1 and G2 eGFR categories alone do not establish CKD; persistent albuminuria, structural abnormalities or another marker of kidney damage must be present. A preserved filtration estimate can coexist with clinically important glomerular injury. Use previous results, repeat testing and clinical history to establish chronicity rather than assigning CKD from one measurement.
Apply it
A patient has eGFR 82 mL/min/1.73 m² and urine albumin-creatinine ratios of 180 and 210 mg/g four months apart. Persistent albuminuria establishes CKD despite an eGFR that falls within the G2 category.
Common pitfall: Labeling every G2 result CKD overdiagnoses disease. Dismissing persistent albuminuria because serum creatinine is normal misses kidney damage and an opportunity for risk reduction.
Identify & Evaluate Patients with Chronic Kidney Disease · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
5.How should an elevated urine albumin-creatinine ratio be interpreted?
Urine albumin-creatinine ratio estimates albumin excretion while reducing the effect of urine concentration. Categories are A1 below 30 mg/g, A2 from 30 to 300 mg/g and A3 above 300 mg/g. Albuminuria complements eGFR when estimating progression and cardiovascular risk. Confirm an unexpected elevated result, preferably with a first-morning specimen, because exercise, infection, menstruation and other transient conditions can increase urinary albumin without establishing chronic disease.
Apply it
A runner's UACR is 95 mg/g after a race during a febrile illness. Repeat a first-morning sample after recovery, then assess persistence rather than immediately attributing the result to chronic diabetic kidney disease.
Common pitfall: A urine dipstick and UACR are not interchangeable measurements. One transiently elevated UACR cannot establish the chronicity required for a CKD diagnosis by itself.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · Identify & Evaluate Patients with Chronic Kidney Disease
6.Which patients need kidney screening beyond serum creatinine?
Patients at risk for CKD should be assessed with both estimated GFR and urine albumin measurement because these identify different dimensions of disease. Diabetes, hypertension, cardiovascular disease and relevant family history increase the value of testing. Evaluate the likely cause using history, examination, urine findings and selected imaging or additional tests. Hematuria with substantial proteinuria or systemic features should prompt investigation beyond an assumption of uncomplicated hypertensive kidney disease.
Apply it
A patient with diabetes has a reassuring creatinine result but has never had urine albumin measured. Obtain UACR alongside eGFR; identifying albuminuria would change risk assessment, counseling and consideration of kidney-protective treatment during follow-up.
Common pitfall: Waiting for symptoms misses early CKD, which is often silent. Attributing all kidney abnormalities in a patient with diabetes to diabetes can miss another disease.
Identify & Evaluate Patients with Chronic Kidney Disease · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Stage 3 CKD11–13%
7.How do GFR and albuminuria jointly define stage 3 risk?
Stage 3 CKD includes G3a, with eGFR 45–59 mL/min/1.73 m², and G3b, with eGFR 30–44. Albuminuria, cause and trajectory refine risk within either category. Two people with the same eGFR can have very different progression and cardiovascular risks when albuminuria differs. Serial results help distinguish stable disease from meaningful deterioration. Use an externally validated kidney failure risk equation where appropriate rather than treating every stage 3 patient identically.
Apply it
Two patients have eGFR 42. One has stable A1 albuminuria; the other has A3 albuminuria and declining function. The second needs closer progression assessment and risk-based planning despite sharing the same GFR category.
Common pitfall: Stage labels do not supply the entire prognosis. A single small eGFR fluctuation may reflect biological variation rather than a sustained change in disease trajectory.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
8.When does a creatinine rise after ACE inhibitor therapy need investigation?
ACE inhibitors and ARBs reduce intraglomerular pressure, so a modest early creatinine rise can accompany kidney protection. Check blood pressure, creatinine and potassium within two to four weeks after initiation or dose escalation. A creatinine rise exceeding 30% within four weeks warrants evaluation for contributors such as volume depletion, interacting drugs or renovascular disease. Hyperkalemia should be actively managed when feasible rather than automatically abandoning beneficial therapy after any elevation.
Apply it
Creatinine increases from 1.6 to 2.2 mg/dL two weeks after an ARB increase. The 37.5% rise prompts evaluation of volume status, NSAID exposure, potassium and other contributors before deciding whether therapy can safely continue.
Common pitfall: Neither automatic continuation nor automatic permanent discontinuation is appropriate after a substantial rise. Combining an ACE inhibitor with an ARB adds harm without routine kidney benefit.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
9.Who should receive an SGLT2 inhibitor, and how should early changes and interruptions be managed?
SGLT2 inhibitors reduce proximal sodium-glucose reabsorption, increase sodium delivery to the macula densa and restore tubuloglomerular feedback, reducing intraglomerular pressure. KDIGO recommends treatment for type 2 diabetes with CKD and eGFR at least 20 mL/min/1.73 m². Once initiated, continuation below 20 is reasonable unless treatment is not tolerated or KRT begins; continuation is distinct from initiating below the recommended threshold. A small reversible initial eGFR dip generally does not require discontinuation. Select an agent with the relevant indication: empagliflozin is labeled to reduce kidney and cardiovascular outcomes in adults with CKD at risk of progression, with a recommended dose of 10 mg once daily. Ertugliflozin is labeled for glycemic control in adults with type 2 diabetes, and use is not recommended below eGFR 45. Correct volume depletion before initiation. Withhold empagliflozin at least three days, or ertugliflozin at least four days, before planned surgery or prolonged-fasting procedures when possible. Resume when clinically stable and oral intake has resumed.
Apply it
A stable patient with type 2 diabetes, G3b CKD and eGFR 34 meets KDIGO's initiation threshold. Empagliflozin 10 mg once daily can address its labeled CKD indication after volume assessment. A later well-tolerated decline below eGFR 20 does not alone require stopping. For planned surgery, arrange withholding at least three days beforehand and restart only after clinical stability and resumed intake.
Common pitfall: Do not apply one agent's indication or kidney-function restrictions to every SGLT2 inhibitor. Progressive AKI with hypotension differs from an expected early dip. Ketoacidosis can occur without marked hyperglycemia, particularly during fasting, surgery or critical illness.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease · DailyMed - JARDIANCE- empagliflozin tablet, film coated · DailyMed - STEGLATRO- ertugliflozin tablet, film coated
10.Why is cardiovascular prevention central to stage 3 CKD care?
CKD increases cardiovascular risk through overlapping vascular, metabolic and hemodynamic mechanisms. Management therefore combines smoking cessation, appropriate physical activity, blood pressure treatment, diabetes care and indicated lipid-lowering therapy. KDIGO recommends statin or statin/ezetimibe treatment for adults aged at least 50 with eGFR below 60 who are not receiving chronic dialysis or a kidney transplant. Treatment selection still requires attention to interactions, tolerance and the patient's broader cardiovascular history.
Apply it
A 62-year-old with G3b CKD is not receiving dialysis and has no prior myocardial infarction. Review statin-based prevention alongside blood pressure, smoking and activity rather than waiting for a cardiovascular event before addressing vascular risk.
Common pitfall: A modest LDL concentration does not erase CKD-associated cardiovascular risk. Recommendations for initiating lipid treatment in nondialysis CKD should not be assumed identical for dialysis patients.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
11.Which medication exposures can destabilize kidney function during illness?
Volume depletion can magnify medication-related kidney risk. NSAIDs impair prostaglandin-mediated afferent vasodilation, while ACE inhibitors or ARBs reduce efferent arteriolar tone; diuretics may further lower circulating volume. Review these exposures when an ill patient develops hypotension or rising creatinine. Any temporary medication interruption should include a clear reassessment and restart plan. SGLT2 inhibitors require particular attention during fasting or critical illness because of increased ketosis risk.
Apply it
A patient taking an ARB and diuretic develops diarrhea and adds naproxen for back pain. Assess perfusion, creatinine and potassium, stop the NSAID, and individualize temporary medication changes with explicit follow-up and restart instructions.
Common pitfall: A blanket instruction to stop medicines indefinitely can remove protective treatment. Medication safety requires identifying the acute problem and arranging reassessment, not simply issuing a list.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
12.How should blood pressure targets be applied in nondialysis CKD?
Blood pressure interpretation depends on measurement technique and treatment tolerance. KDIGO suggests a systolic target below 120 mmHg for adults with high blood pressure and nondialysis CKD when tolerated, using standardized office measurement. This target cannot be transferred directly to a hurried routine reading. Consider symptomatic postural hypotension, frailty and fall risk when individualizing intensity. Sodium reduction and assessment of volume excess support pharmacologic treatment rather than functioning as unrelated counseling tasks.
Apply it
A patient's rushed clinic systolic reading is 138 mmHg, but standardized readings are lower and standing causes dizziness. Confirm technique and orthostatic symptoms before increasing medication solely to force the routine reading below 120 mmHg.
Common pitfall: Treating an unstandardized reading as equivalent to a research-quality measurement can cause overtreatment. A numerical goal does not override symptomatic hypotension or substantial treatment intolerance.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
13.When can creatinine-based eGFR mislead medication decisions?
Creatinine generation varies with muscle mass, diet and other nonfiltration factors. Severe muscle wasting can make creatinine-based eGFR overestimate kidney function, affecting diagnosis and drug safety. When greater accuracy would change a clinical decision, combined creatinine-cystatin C estimation or measured GFR may be useful. Medication decisions must also follow the product's specified kidney function metric. During rapidly changing kidney function, steady-state estimating equations may poorly represent current clearance.
Apply it
A markedly sarcopenic patient has an unexpectedly reassuring creatinine-based eGFR while receiving a renally cleared drug with a narrow therapeutic range. Seek a more reliable filtration estimate and appropriate drug monitoring before accepting the apparent clearance.
Common pitfall: Automatically treating every reported eGFR as precise can cause accumulation. Cystatin C also has nonfiltration influences, so additional testing requires clinical interpretation rather than blind substitution.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Stages 4 & 5 CKD not on KRT19–21%
14.When should dialysis begin in advanced CKD?
Dialysis initiation should integrate symptoms, signs, quality of life, preferences, GFR and laboratory abnormalities rather than follow a single creatinine or eGFR threshold. Indications include manifestations attributable to kidney failure, medically resistant electrolyte or acid-base disturbances, inability to control volume or blood pressure, and progressive nutritional deterioration despite intervention. Uremic pericarditis or refractory pulmonary edema demands urgent action. Stable low eGFR without these problems supports close assessment and preparation rather than automatic initiation.
Apply it
A patient with eGFR 9 has refractory pulmonary edema despite appropriate medical treatment. The uncontrolled volume complication supports dialysis initiation; a second patient with the same eGFR but stable nutrition and no attributable symptoms needs individualized surveillance.
Common pitfall: Waiting for an arbitrary lower eGFR can delay necessary treatment. Starting solely because eGFR crosses a number can expose an otherwise stable patient to avoidable burdens.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
15.How should kidney failure treatment choices be matched to daily life?
Treatment education should compare transplantation, home and in-center dialysis options, and comprehensive conservative care before a crisis limits choice. Explore the person's goals, home conditions, support, work, dexterity, cognition and willingness to perform treatment tasks. Practical barriers may be modifiable through training or assistance. Explain that a treatment plan can evolve as health or preferences change. Shared choice requires realistic discussion of benefits and burdens rather than presenting one modality as universally best.
Apply it
A working parent wants fewer daytime clinic visits but worries about managing equipment. Discuss home treatment schedules, training and available support, then compare these with in-center treatment and transplantation according to the patient's priorities and clinical suitability.
Common pitfall: Assuming that age alone determines modality overlooks function and support. Offering education only after urgent catheter placement may unnecessarily narrow the patient's practical options.
16.What does comprehensive conservative kidney care include?
Conservative management is active kidney failure care without dialysis or transplantation. It includes symptom relief, treatment of manageable complications, support for quality of life and advance care planning. Decisions should reflect informed goals and expected treatment burdens rather than assumptions about worthiness for care. Palliative support can accompany kidney care before the end of life. Review changing preferences, caregiver needs and plans for worsening symptoms so that declining dialysis does not mean losing clinical support.
Apply it
A patient with severe frailty declines dialysis after an informed discussion. Continue management of breathlessness, edema, itching and anemia where appropriate, and coordinate family support and advance planning rather than discharging the patient from kidney follow-up.
Common pitfall: Equating conservative care with abandonment prevents symptom treatment and meaningful planning. A patient's informed refusal of dialysis does not imply refusal of all medical interventions.
17.Which tests help distinguish CKD anemia from reversible causes?
Reduced erythropoietin production contributes to CKD anemia, but anemia should not be attributed to kidney disease without evaluation. Initial assessment includes a complete blood count, reticulocytes, ferritin and transferrin saturation. Findings may prompt assessment for bleeding, nutritional deficiency, inflammation, hemolysis or another marrow process. Correcting a reversible cause can improve symptoms and treatment response. Macrocytosis, unexpected reticulocytosis or an abrupt hemoglobin fall is a clue that isolated erythropoietin deficiency is insufficient to explain the presentation.
Apply it
A patient with G4 CKD develops a rapid hemoglobin decline and new microcytosis. Obtain iron indices and investigate potential blood loss instead of proceeding directly to ESA escalation under the assumption that CKD explains the change.
Common pitfall: A low hemoglobin value alone does not identify the mechanism. Starting an ESA before evaluating iron deficiency or bleeding can delay diagnosis and produce an inadequate response.
KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease
18.When should iron be initiated, reassessed or withheld in nondialysis CKD?
Ferritin reflects stores but also rises with inflammation. Increased hepcidin can restrict intestinal absorption and release of stored iron, so iron availability may be low despite a nonlow ferritin. For anemia in nondialysis CKD, KDIGO suggests initiating iron when ferritin is below 100 ng/mL with TSAT below 40%, or ferritin is 100 to below 300 ng/mL with TSAT below 25%. These are initiation criteria, not treatment targets. Select oral or intravenous iron according to deficiency severity, prior response, tolerance, access, cost and preference. An inadequate response after one to three months of an optimal oral regimen supports switching to intravenous iron; limiting intolerance can also justify a change. Reassess hemoglobin, ferritin and TSAT approximately every three months in nondialysis CKD, sooner when clinically indicated by bleeding, treatment changes or an unexpected response. KDIGO advises considering withholding routine iron when ferritin exceeds 700 ng/mL or TSAT reaches 40%, and temporarily suspending iron during systemic infection.
Apply it
A patient with G4 CKD, anemia, ferritin 80 ng/mL and TSAT 32% meets the first initiation criterion. Another with ferritin 180 ng/mL and TSAT 22% meets the second; ferritin 180 with TSAT 28% does not. If an optimal oral regimen produces an inadequate response after two months and constipation limits adherence, switch to intravenous iron after reassessing contributors such as blood loss. At subsequent review, ferritin 740 ng/mL or TSAT 40% supports considering withholding routine iron. If systemic infection develops, suspend iron temporarily and reassess after the infection resolves.
Common pitfall: Do not require TSAT below 20% in every nondialysis initiation decision or use ferritin alone to exclude iron restriction. Initiation criteria do not define values to pursue indefinitely. Escalating iron despite high indices, systemic infection or absent response can miss the need to withhold treatment or investigate another anemia mechanism.
KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease
19.How should ESA treatment balance guideline recommendations and U.S. epoetin alfa labeling?
Correct reversible anemia causes before ESA treatment and individualize the decision using symptoms, transfusion risk and comorbidities. KDIGO recommends maintaining hemoglobin below 11.5 g/dL in adults treated with an ESA. U.S. epoetin alfa labeling gives drug-specific dose instructions: in adults not receiving dialysis, consider initiation only below 10 g/dL when declining hemoglobin suggests likely transfusion and reducing transfusion-related risks is a goal; reduce or interrupt the dose if hemoglobin exceeds 10 g/dL. In adults receiving dialysis, initiate below 10 g/dL and reduce or interrupt when hemoglobin approaches or exceeds 11 g/dL. Use the lowest dose sufficient to reduce transfusion requirements. Uncontrolled hypertension is a contraindication. Monitor hemoglobin and blood pressure and investigate hyporesponsiveness rather than escalating repeatedly without identifying iron restriction, inflammation or blood loss.
Apply it
An adult with G4 CKD who is not receiving dialysis reaches hemoglobin 10.4 g/dL on epoetin alfa. The U.S. label directs dose reduction or interruption even though the value is below KDIGO's 11.5 g/dL maintenance boundary. A dialysis patient approaching 11 g/dL also requires dose review under the label.
Common pitfall: A guideline maintenance boundary is not interchangeable with a specific drug's U.S. dose-adjustment instructions. Normalizing hemoglobin increases cardiovascular and thrombotic risk, and an ESA does not provide immediate correction of severe symptomatic anemia.
KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease · DailyMed - EPOGEN- epoetin alfa solution
20.How should calcium, phosphate and PTH trends be interpreted together?
CKD mineral and bone disorder involves interacting changes in phosphate handling, calcium balance, vitamin D metabolism and parathyroid activity. Treatment decisions should use serial calcium, phosphate and PTH assessments considered together. One abnormal value may reflect variability or an adaptive response rather than a mandate for immediate medication escalation. Persistently abnormal patterns are more informative. A treatment that improves one number can worsen another, such as increasing calcium exposure while trying to control phosphate.
Apply it
A patient has progressively rising phosphate and PTH across several visits while calcium is high-normal. Review diet, medication exposure and the overall trend before adding a calcium-containing binder solely to correct phosphate on the latest report.
Common pitfall: Treating laboratory values independently can create conflicting therapies. A single elevated PTH does not establish the same treatment need as a sustained, progressive rise.
21.What should be assessed before treating rising PTH in nondialysis CKD?
The optimal PTH concentration in nondialysis CKD is uncertain. A progressively rising or persistently elevated PTH should prompt assessment for modifiable factors, including hyperphosphatemia, high phosphate intake, hypocalcemia and vitamin D deficiency. Modest increases may be adaptive. Calcitriol and vitamin D analogues are not recommended routinely for all adults with nondialysis CKD; selected severe, progressive hyperparathyroidism in advanced CKD requires a different assessment from an isolated mild elevation.
Apply it
A patient with G4 CKD has a gradually rising PTH, low vitamin D and increased phosphate intake from processed foods. Address these contributors and reassess trends before assuming that immediate active vitamin D therapy is the best response.
Common pitfall: Applying dialysis PTH guidance directly to nondialysis CKD ignores important differences. Correcting vitamin D deficiency and prescribing an active vitamin D analogue are different interventions.
22.When is phosphate-lowering treatment appropriate before dialysis?
Phosphate-lowering decisions should respond to progressively or persistently elevated serum phosphate rather than automatically treating all advanced CKD patients with normal phosphate. Dietary assessment should consider phosphate source and nutritional adequacy; additives can contribute readily absorbed phosphate. When binders are indicated, calcium exposure, other laboratory findings and treatment burden influence selection. Serial assessment helps avoid replacing a biochemical concern with hypercalcemia or excessive dietary restriction that compromises energy and protein intake.
Apply it
A patient with G4 CKD has repeatedly elevated phosphate and relies on processed convenience meals. Review phosphate additives and overall nutrition with a dietitian, then consider medication in the context of calcium levels and the persistent laboratory pattern.
Common pitfall: Prescribing binders solely because CKD is advanced lacks the same rationale as treating persistent hyperphosphatemia. Broad food bans can worsen nutritional intake without targeting major phosphate sources.
23.Why should veins be preserved before dialysis is required?
Future hemodialysis access depends on usable vessels and central venous outflow. Repeated venipuncture, peripheral devices and central lines can damage potential access sites or cause stenosis. In advanced CKD with a meaningful likelihood of hemodialysis, coordinate vascular preservation with the kidney team and other clinicians. Avoid an automatic PICC decision without considering future access. Vessel preservation belongs within an individualized kidney failure treatment plan, including whether hemodialysis is actually intended.
Apply it
A hospitalized patient with progressive G4 CKD needs prolonged intravenous treatment. Before placing a PICC, involve nephrology and the vascular access team to select a route that meets the immediate need while protecting future access options.
Common pitfall: Protecting veins only after dialysis starts is too late for some injuries. Equally, access preservation should reflect the patient's treatment plan rather than override an urgent clinical need.
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
24.How can predicted kidney failure risk guide treatment preparation?
Preparation should reflect the likelihood and timing of kidney failure, the person's trajectory and their preferred treatment. KDIGO supports using validated kidney failure risk prediction in appropriate CKD populations; a two-year risk above 40% can help guide modality education, access preparation and transplant referral alongside clinical criteria. Planning ahead permits informed choices and time for access readiness. A risk estimate informs preparation but does not itself indicate that dialysis must begin immediately.
Apply it
A patient with G4 CKD has rapid progression and a high validated two-year kidney failure risk. Begin transplant and modality discussions and access planning now, while continuing medical management and assessing symptoms rather than scheduling dialysis solely from the risk score.
Common pitfall: Using eGFR alone can produce preparation that is too early or too late. A prediction equation must be appropriate for the patient and interpreted with trajectory and goals.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
25.When should persistent metabolic acidosis prompt treatment in advanced CKD?
Declining kidney acid excretion can lower serum bicarbonate, but confirm an unexpected low result and assess gastrointestinal bicarbonate loss, medications and other acid-base disorders before attributing it to CKD. KDIGO practice point 3.10.1 advises considering pharmacologic treatment, with or without dietary intervention, to prevent acidosis with potential clinical implications; bicarbonate below 18 mmol/L in adults is its example, not a universal mandatory treatment threshold. Practice point 3.10.2 calls for monitoring so treatment does not raise bicarbonate above the laboratory's upper normal limit or adversely affect blood pressure, potassium or fluid status. Sodium-containing alkali can aggravate edema and requires careful selection and titration. Bicarbonate correction has not established a kidney-failure prevention benefit. Severe medically resistant acidosis can support dialysis initiation.
Apply it
A patient with G5 CKD has bicarbonate 17 mmol/L on two measurements and mild edema. After confirming metabolic acidosis and assessing alternative causes, consider pharmacologic alkali rather than waiting for a further numerical decline. If oral sodium bicarbonate is selected, use cautious titration with reassessment of bicarbonate, potassium, blood pressure, weight and edema. Worsening congestion argues against increasing the sodium load and may require reducing or stopping sodium-containing alkali, revising volume management and considering dietary intervention with attention to potassium and nutrition. Severe acidosis that remains medically resistant requires assessment for dialysis.
Common pitfall: One low total carbon dioxide result does not establish the acid-base mechanism. The adult bicarbonate example below 18 mmol/L guides consideration of treatment; it does not mandate the same prescription for every patient. Do not promise that correcting bicarbonate prevents kidney failure or pursue biochemical normalization at the expense of worsening fluid overload.
KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
Kidney Replacement Therapies57–59%
26.How does a hemodialyzer remove dissolved waste?
Blood flows through hollow fibers while dialysate flows outside them, separated by a semipermeable membrane. Small dissolved substances move mainly by diffusion down concentration gradients. Keeping blood and dialysate moving maintains these gradients during treatment. Membrane characteristics, flow and treatment time influence clearance. Dialysis replaces only part of kidney function, so waste removal does not restore all endocrine, metabolic or continuous regulatory functions of healthy kidneys.
Apply it
A patient asks whether dialysate is infused directly into the bloodstream. Explain the separate blood and dialysate compartments and selective movement across the membrane, then distinguish dissolved-waste clearance from the pressure-driven removal of excess water.
Common pitfall: Dialysis does not work by mixing blood with cleaning fluid. Improved small-solute clearance also does not demonstrate that volume, nutrition and every uremic problem are adequately controlled.
27.How does ultrafiltration differ from diffusion?
Ultrafiltration removes plasma water across the dialyzer membrane through a pressure gradient, whereas diffusion primarily transfers dissolved substances down concentration gradients. Fluid removal must be matched to the patient's volume burden and ability to refill the circulation from tissues. A technically achieved fluid goal can still cause harm when removal exceeds hemodynamic tolerance. Evaluate symptoms, blood pressure, treatment time and target weight together instead of equating successful machine delivery with appropriate physiology.
Apply it
A patient reaches the prescribed postdialysis weight but repeatedly develops cramps and hypotension. The delivered fluid removal may be excessive for the available refill rate, prompting review of target weight, treatment duration and interdialytic gains with the patient.
Common pitfall: A high waste-clearance result does not prove safe fluid removal. Removing all accumulated weight over an unchanged short session can exceed the patient's circulatory tolerance.
Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
28.How is a weight-normalized ultrafiltration rate calculated?
For a specified calculation, divide net ultrafiltration volume in milliliters by treatment hours and the chosen reference weight in kilograms. State which weight is used and whether intake or infusions are already included in the net goal. The result describes fluid removal intensity, not a universal safety guarantee. Increasing treatment time lowers the rate for the same volume and weight. Clinical tolerance, residual kidney function and volume status remain essential to interpretation.
Apply it
Using postdialysis weight, removing 2,800 mL over four hours from a 70-kg patient gives 2,800 divided by 4 divided by 70, or 10 mL/kg/hour. Extending treatment to five hours lowers this to 8.
Common pitfall: Confusing liters with milliliters creates a thousandfold error. An accurately calculated rate still cannot establish that the prescribed target weight or removal volume is appropriate.
Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
29.Why is target weight a repeated clinical assessment?
Target weight estimates the postdialysis weight that balances volume control with treatment tolerance. It changes with nutritional status, illness, tissue gain or loss and residual kidney function. A target that is too high can leave chronic congestion; one that is too low can cause hypotension and organ hypoperfusion. Use symptoms, examination, blood pressure patterns and longitudinal information together. No single physical sign or machine value perfectly establishes euvolemia in every patient.
Apply it
After several weeks of poor intake, a patient's recorded target weight remains unchanged, but edema and breathlessness develop. Loss of tissue mass may conceal fluid accumulation, so reassess volume rather than assuming the unchanged scale target is still valid.
Common pitfall: Target weight is not a permanent baseline. Edema alone is also imperfect, so decisions should integrate the broader clinical pattern and response to cautious changes.
Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
30.Which mechanisms contribute to intradialytic hypotension?
Intradialytic hypotension can occur when ultrafiltration outpaces plasma refill or cardiovascular compensation is inadequate. Cardiac disease, autonomic dysfunction, meals and medication timing may contribute. Symptomatic episodes require immediate clinical assessment and adjustment of fluid removal according to the situation. Recurrent episodes warrant review of target weight, ultrafiltration intensity, treatment time and contributing illness. Routine acceptance of low pressures risks repeated hypoperfusion even when the planned fluid goal is reached.
Apply it
A patient becomes dizzy late in treatment after a large interdialytic gain. Assess the episode and reduce or pause ultrafiltration as appropriate, then review whether longer treatment and lower sodium-driven weight gain could prevent recurrence during subsequent sessions.
Common pitfall: Treating every episode only with fluid replacement leaves the underlying prescription problem unresolved. Conversely, raising target weight automatically can perpetuate chronic overload in a congested patient.
Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
31.Why should volume be assessed before escalating dialysis blood pressure therapy?
Extracellular volume excess is an important contributor to hypertension in dialysis. Review interdialytic weight gain, symptoms, target weight and the dialysis prescription before assuming that another antihypertensive is the only solution. Volume reduction must remain tolerable; overly aggressive ultrafiltration can cause hypotension despite chronic congestion. Medication remains useful when indicated, but effective management integrates sodium intake, fluid removal, treatment time and cardiovascular comorbidity rather than treating blood pressure as an isolated number.
Apply it
A patient has persistent hypertension, increasing interdialytic gains and new orthopnea. Reassess congestion and target weight while reviewing medication, rather than simply adding another agent without addressing the likely volume contribution to the elevated pressure.
Common pitfall: A lower predialysis pressure does not necessarily mean euvolemia. Aggressively removing fluid in a short session can exchange chronic overload for recurrent intradialytic hypoperfusion.
Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
32.Which blood pressure measurements best describe interdialytic control?
Predialysis and postdialysis pressures are convenient but incompletely represent blood pressure between treatments. Home measurements and interdialytic ambulatory monitoring can better characterize the patient's usual burden and identify discrepancies with unit readings. Interpret results alongside volume status, symptoms and cardiovascular conditions. Dialysis blood pressure targets require individualization because evidence does not support simply importing a nondialysis office target. Measurement technique and timing should remain consistent enough to make trends meaningful.
Apply it
A patient's unit pressures are variable, and medication increases cause dizziness at home. Obtain a structured home blood pressure record or ambulatory assessment to clarify interdialytic control before making further changes based only on dialysis-unit measurements.
Common pitfall: Applying the nondialysis standardized systolic target to every dialysis reading ignores population and measurement differences. One pre-treatment measurement should not determine the entire antihypertensive plan.
Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
33.How does dietary sodium drive interdialytic weight gain?
Sodium intake promotes thirst and fluid consumption, increasing the volume that must be removed during dialysis. Counseling should therefore connect food choices to thirst, weight gain and treatment symptoms rather than discussing fluid restriction alone. Identify processed foods, sauces and other concentrated sodium sources that fit the patient's eating pattern. Lower sodium intake can reduce removal demands, but the plan must remain practical and nutritionally adequate rather than replacing meals with broad prohibitions.
Apply it
A patient reports constant thirst despite trying to limit drinks and frequently eats packaged soups. Review sodium labels and suitable meal alternatives, explaining how reducing sodium can make the fluid plan more achievable between dialysis sessions.
Common pitfall: Repeating a fluid limit without addressing sodium can leave the main thirst driver untouched. Potassium-containing salt substitutes also require review before being recommended as an alternative.
Eating & Nutrition for Hemodialysis · Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
34.Why does residual kidney function matter during hemodialysis?
Residual kidney function contributes to continuous water and solute removal between dialysis sessions, even when it cannot sustain health without KRT. Declining urine production can increase fluid removal requirements and change electrolyte management. Review urine trends, nephrotoxic exposures and episodes of hypotension rather than assuming all remaining function is irrelevant. Dialysis and medication plans should account for measured or clinically assessed residual function; urine volume alone does not fully quantify solute clearance.
Apply it
A patient's urine output falls substantially over several weeks while interdialytic gains rise. Reassess the fluid plan, medication exposures and dialysis prescription rather than assuming that previously successful fluid allowances remain appropriate after residual function declines.
Common pitfall: Being on dialysis does not make nephrotoxic exposure harmless. Conversely, producing urine does not prove adequate potassium or uremic-solute clearance without appropriate clinical and laboratory assessment.
Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions · Hemodialysis
35.Why does delivered treatment time matter beyond a clearance number?
Shortened or missed hemodialysis reduces the opportunity for solute and fluid removal. Compressing the same fluid goal into less time increases ultrafiltration intensity and may worsen tolerance. Review actual treatment duration, interruptions, access function and symptoms when judging effectiveness. A small-solute clearance measure addresses only part of treatment quality. Blood pressure, congestion, nutrition and patient experience also matter, so one satisfactory result should not excuse repeated early termination or unresolved clinical problems.
Apply it
A patient repeatedly leaves an hour early because transport arrives before treatment ends. Coordinate transport and reassess delivered therapy rather than documenting only the prescribed schedule or attempting to remove the entire fluid goal faster before departure.
Common pitfall: Prescribed hours are not necessarily delivered hours. A reassuring laboratory adequacy measure cannot by itself rule out unsafe fluid removal or the consequences of recurrent shortened sessions.
Hemodialysis · Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
36.How does physical examination help monitor an arteriovenous access?
Clinical access monitoring includes inspection, palpation and auscultation together with treatment observations. Changes in thrill, bruit, pulse character, arm swelling or the access appearance can indicate dysfunction. Examine trends relative to the person's usual findings instead of relying only on a machine pressure. Difficult cannulation, prolonged bleeding and reduced delivered blood flow add important evidence. A concerning pattern should prompt timely evaluation for a clinically significant lesion rather than waiting for complete access failure.
Apply it
An established fistula develops a more pulsatile segment, altered bruit and new arm swelling. Combine these examination changes with dialysis flow and cannulation information to arrange access evaluation while the fistula is still functioning.
Common pitfall: The presence of any thrill does not prove normal access function. Conversely, an isolated surveillance abnormality without clinical indicators does not automatically justify an intervention.
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
37.Which treatment changes suggest clinically important access stenosis?
New difficulty achieving prescribed blood flow, sustained venous pressure changes, repeated cannulation problems, prolonged postneedle bleeding or unexplained loss of delivered clearance can signal access dysfunction. These findings should be interpreted with physical examination and the treatment context. When clinical indicators suggest a significant lesion, confirmatory imaging and timely management may preserve access. KDOQI distinguishes clinically indicated evaluation from preemptive treatment of an anatomic stenosis that has no associated clinical evidence of dysfunction.
Apply it
A fistula previously supporting usual blood flow now triggers repeated venous pressure alarms and bleeds longer after needle removal. Evaluate possible outflow dysfunction rather than attributing the entire pattern to one difficult cannulation or simply reducing treatment flow indefinitely.
Common pitfall: Prolonged bleeding is not always explained by anticoagulation. Intervening on every imaging-detected narrowing, however, ignores the requirement to connect anatomy with clinically significant dysfunction.
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
38.When does a change in access thrill require urgent action?
An absent or abruptly changed thrill can indicate thrombosis or severe flow limitation and requires prompt access assessment. Do not continue routine cannulation of an access that appears nonfunctional. Timely communication with the access team can preserve options for salvage and avoid unnecessary delays in dialysis. Assess associated pain, swelling, infection findings and distal perfusion. A cold, painful hand introduces concern for threatened limb perfusion and changes the urgency of evaluation.
Apply it
A patient notices that the usual fistula vibration disappeared overnight. At the dialysis unit, no thrill is palpable. Stop the routine cannulation pathway and arrange urgent evaluation for access thrombosis and a plan for necessary dialysis.
Common pitfall: Waiting until the next scheduled clinic review may reduce salvage opportunities. A painful cold hand should not be dismissed as the same problem as uncomplicated access thrombosis.
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
39.How should fistula and graft choices fit an ESKD Life-Plan?
The ESKD Life-Plan aligns access decisions with expected treatment needs, vessel anatomy, prognosis, preferences and future options. A fistula may offer advantages when it matures and functions, but it is not automatically the best access for every person. A graft or another strategy may better fit limited preparation time or unsuitable vessels. Consider the whole access sequence and likelihood of use rather than pursuing one access type as an isolated quality goal.
Apply it
An older patient needs dialysis soon and has vessels unlikely to support successful fistula maturation. Discuss a graft and the broader access plan rather than recommending repeated fistula attempts without considering catheter exposure, treatment timing and the patient's goals.
Common pitfall: A universal fistula-first rule can increase procedures and catheter time in selected patients. Choosing access requires individualized planning rather than equating one device with good care.
KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
40.Why do dialysis catheters carry greater bloodstream infection risk?
A central venous catheter provides a persistent route from skin and manipulated hubs to the bloodstream. This makes infection prevention especially important and contributes to higher bloodstream infection risk than arteriovenous access. Reduce unnecessary catheter exposure through an individualized access plan while maintaining meticulous care whenever a catheter is needed. Patient education should cover keeping the dressing protected, avoiding unauthorized manipulation and promptly reporting fever, chills, drainage or other concerning changes.
Apply it
A patient starting dialysis through a catheter asks why permanent access planning continues despite reliable catheter flow. Explain the infection risk and discuss suitable longer-term options while reinforcing dressing protection and prompt reporting of symptoms during catheter use.
Common pitfall: Good catheter flow does not indicate low infection risk. Telling a patient simply to avoid touching the catheter is insufficient without practical instructions and a reporting plan.
Infections and Patients on Dialysis · Best Practices for Bloodstream Infection Prevention in Dialysis Setting
41.How does catheter hub disinfection interrupt infection transmission?
Catheter hubs can become contaminated during connections and disconnections, allowing organisms to enter the bloodstream. Scrubbing hubs with an appropriate antiseptic at access and disconnection points reduces this route of transmission. Follow the approved product's contact and drying requirements and maintain aseptic handling afterward. Clean gloves alone do not disinfect a hub. Standardized procedures, observed practice and feedback help make this protection reliable across staff members and treatment shifts rather than dependent on individual memory.
Apply it
During an observation, a staff member changes gloves but connects the bloodline without disinfecting the catheter hub. Correct the missed hub step and reinforce the unit procedure, including antiseptic use and required drying before connection.
Common pitfall: Gloves do not replace surface antisepsis. A hub that was cleaned earlier can be recontaminated if touched or handled improperly before the sterile connection is completed.
Best Practices for Bloodstream Infection Prevention in Dialysis Setting
42.Why must hand hygiene and aseptic technique be audited separately?
Hand hygiene reduces organism transfer, while aseptic technique protects critical access and connection sites during procedures. Both are necessary because success at one does not guarantee the other. Gloves can become contaminated, and clean hands do not make a contaminated connection safe. CDC prevention practices include staff education, competency assessment and observations with feedback. Auditing specific steps identifies actionable failures more effectively than a general statement that staff are following infection precautions.
Apply it
An audit finds good hand hygiene but frequent touching of prepared catheter connections. Target training and feedback to aseptic handling while continuing hand hygiene observation, because the two measures address related but distinct opportunities for bloodstream contamination.
Common pitfall: A high hand hygiene percentage does not prove that catheter care is safe. Wearing gloves throughout several tasks can spread contamination when task-specific changes are omitted.
Best Practices for Bloodstream Infection Prevention in Dialysis Setting
43.How should bloodstream infection surveillance improve unit practice?
Surveillance turns individual infections into a measurable pattern that can guide prevention. Review bloodstream infection data, access types and practice observations, then share results with frontline staff. CDC's core interventions combine surveillance and feedback with hand hygiene, access care, staff competency and patient education. A rising rate should trigger investigation of processes and patterns rather than blame alone. Reassessment after an intervention determines whether the change improved practice and patient outcomes.
Apply it
A dialysis unit detects an increase in catheter-associated infections over several months. Review cases and access exposure, observe hub and dressing practices, provide staff feedback and track subsequent infection trends rather than responding only to each infection separately.
Common pitfall: Counting infections without feeding results back to the team misses the preventive purpose. Comparing raw counts alone can mislead when catheter exposure or the patient population changes.
Best Practices for Bloodstream Infection Prevention in Dialysis Setting
44.Which findings make fever during dialysis concerning for bloodstream infection?
Fever or chills during dialysis require prompt clinical assessment, especially in a patient with a central venous catheter. A normal-looking exit site does not exclude bloodstream infection because the infection may involve the catheter lumen or another source. Assess hemodynamic stability, access findings and other potential infections, and obtain appropriate cultures and treatment through the clinical pathway. Prevention education should make clear that patients need not wait for visible drainage before reporting symptoms.
Apply it
A catheter-dependent patient develops shaking chills during treatment but has no exit-site redness. Assess urgently for bloodstream infection and instability, obtain indicated cultures and initiate the appropriate treatment pathway rather than attributing symptoms to room temperature.
Common pitfall: An intact dressing and clean exit site cannot rule out intraluminal infection. Not every intradialytic fever is catheter-related, so evaluate other causes without delaying urgent care.
Infections and Patients on Dialysis · Best Practices for Bloodstream Infection Prevention in Dialysis Setting
45.When does a hemodialysis vaccine responder need a hepatitis B booster?
Hemodialysis patients who respond to hepatitis B vaccination need ongoing protection assessment because antibody levels can decline. CDC recommends annual anti-HBs testing for hemodialysis patients and a booster when anti-HBs falls below 10 mIU/mL. Interpret results within the vaccination and infection history; anti-HBs is not the same as hepatitis B surface antigen. Document the original response and subsequent testing so that waning immunity is recognized rather than assuming a completed series provides lifelong protection.
Apply it
A vaccinated hemodialysis patient previously demonstrated an adequate response but now has anti-HBs of 7 mIU/mL at annual review. Provide the indicated booster under the vaccination protocol instead of treating the old series as permanently sufficient.
Common pitfall: Guidance for immunocompetent vaccine responders cannot simply be applied to hemodialysis patients. A low anti-HBs result does not itself establish active hepatitis B infection.
46.How should hyperkalemia be prevented and treated during hemodialysis care?
Prevention requires review of potassium trends, residual kidney function, treatment delivery, medications, bowel patterns and food intake. Review potassium-containing salt substitutes and missed treatments; a renal dietitian can identify concentrated sources and workable portions without eliminating all fruits and vegetables. Acute treatment has three distinct purposes. Intravenous calcium immediately stabilizes the cardiac membrane when hyperkalemic ECG changes are present but does not lower potassium. Intravenous insulin with glucose temporarily shifts potassium into cells; monitor glucose closely because hypoglycemia can follow. Potassium must also leave the body through dialysis, appropriate binders or urinary excretion when sufficient kidney function permits. Severe or treatment-resistant hyperkalemia in an anuric dialysis patient supports urgent hemodialysis. KDIGO conference consensus recommends cardiac monitoring and a 12-lead ECG when potassium exceeds 6.0 mmol/L; this numerical action threshold reflects consensus guidance. A normal ECG does not exclude dangerous hyperkalemia. Repeat potassium measurements to assess response and detect rebound after shifting therapies, and continue glucose reassessment after insulin.
Apply it
A patient with recurrent high potassium reports using a low-sodium salt substitute; review its potassium content and the complete treatment pattern, then revise food choices with a dietitian. At a later presentation after missed dialysis, the anuric patient has confirmed potassium 6.8 mmol/L and new QRS widening. Establish continuous cardiac monitoring, administer intravenous calcium promptly for cardiac protection, give insulin with glucose for temporary shifting and arrange urgent hemodialysis for potassium removal. Improvement in the ECG after calcium does not mean potassium has fallen. Reassess potassium and glucose during treatment and afterward because shifting can wear off and insulin can cause delayed hypoglycemia.
Common pitfall: Natural or low-sodium labeling does not mean kidney-safe. Dietary counseling cannot replace emergency treatment. Calcium protects the heart without removing potassium, and insulin lowers the measured extracellular concentration without reducing total-body potassium. Neither a normal ECG nor an initial potassium improvement rules out subsequent deterioration or rebound.
Eating & Nutrition for Hemodialysis · KDIGO-Acute-Hyperkalemia-conf-report-FINAL.pdf
47.Why must phosphate binders be coordinated with food?
Phosphate binders act in the gastrointestinal tract by binding phosphate from food, reducing its absorption. Their effectiveness therefore depends on taking them with meals or phosphate-containing snacks according to the prescribed regimen. They do not directly filter phosphate from blood. Persistent hyperphosphatemia should prompt review of timing, food sources, tolerability and treatment delivery before assuming the prescribed amount is insufficient. Binder selection also needs to account for calcium exposure and the patient's broader mineral profile.
Apply it
A patient takes all prescribed binders at bedtime several hours after dinner. Explain their intestinal action and move administration to the relevant meals under the prescribed regimen before interpreting persistent high phosphate as proof of treatment resistance.
Common pitfall: Taking the right total number at the wrong time can undermine benefit. Extra binder tablets are not a substitute for reviewing phosphate additives and meal-specific use.
Eating & Nutrition for Hemodialysis · KDIGO 2017 CKD-MBD Guideline Update
48.Why can dialysis increase concern about protein-energy wasting?
Dialysis removes some protein-related nutrients, and illness, inflammation or poor appetite can further impair nutritional balance. Many patients therefore need a different protein strategy after starting dialysis than during nondialysis CKD. Assess intake, weight trajectory, muscle loss and barriers to eating, and involve a renal dietitian. Albumin is influenced by inflammation and fluid status, so it should not be treated as a pure dietary measure. Nutrition goals must fit the individual's modality and clinical condition.
Apply it
A new dialysis patient continues a restrictive predialysis diet and is losing muscle and appetite. Arrange a dietitian review of protein and energy intake while evaluating inflammation, symptoms and practical barriers instead of reinforcing the old restriction automatically.
Common pitfall: Persisting with an earlier protein restriction can worsen nutritional decline after dialysis starts. A low albumin result alone does not prove that inadequate dietary protein is the sole cause.
Getting More Protein While on Dialysis · Eating & Nutrition for Hemodialysis
49.How should a fluid plan account for hidden intake and urine output?
A fluid plan should reflect residual urine output, treatment schedule, weight gain, symptoms and the patient's usual intake. Foods that melt or contain substantial liquid, such as ice, gelatin and soup, contribute to intake. Teach the person how their choices relate to interdialytic weight and removal demands. There is no single allowance appropriate for every dialysis patient. Review the plan when urine output or clinical condition changes, and combine it with sodium counseling.
Apply it
A patient reports staying within the drink allowance but consumes large bowls of soup and frequent ice. Review all fluid sources and changing urine output together, then agree on measurable substitutions and monitoring rather than assuming deliberate nonadherence.
Common pitfall: Counting only beverages underestimates fluid intake. A fixed allowance copied from another patient may be inappropriate when residual urine production, body size or treatment schedules differ.
Eating & Nutrition for Hemodialysis · Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
50.How does dialysis change medication dosing and reconciliation?
Medication review must consider reduced kidney clearance, residual function, dialysis removal, treatment timing and nonprescription products. Dialyzability is drug-specific. Adult immediate-release levetiracetam labeling recommends 500–1,000 mg every 24 hours for patients using dialysis, plus a 250–500 mg supplemental dose following dialysis. The daily maintenance dose and postdialysis supplement serve different purposes: reduced kidney clearance lowers ongoing dose requirements, while dialysis removal creates a replacement need. Reconcile schedules across specialists, hospital discharge and dialysis records, and assess seizure control, somnolence and behavioral adverse effects.
Apply it
An adult receiving intermittent hemodialysis is prescribed levetiracetam 750 mg every 24 hours. A 250 mg postdialysis supplement is within the labeled supplemental range. An additional full 750 mg maintenance dose exceeds that supplemental range, while omitting the supplement leaves dialysis removal unaddressed. Record both orders distinctly so the supplement is not mistaken for a second routine daily dose.
Common pitfall: Do not transfer levetiracetam's supplement to unrelated medications or use unchanged normal-kidney dosing. Ask about supplements, antacids, analgesics and patient-devised schedule changes as well as prescriptions.
DailyMed - KEPPRA- levetiracetam tablet, film coated KEPPRA- levetiracetam solution · KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease · Hemodialysis
51.How can recurrent missed treatments reveal a solvable care barrier?
Missed treatment can reflect transport failures, work conflicts, depression, symptoms, caregiving duties or misunderstanding of treatment benefit. Explore the reason using specific, nonjudgmental questions and involve the appropriate team members. A practical solution may require social work, schedule adjustment, symptom treatment or reconsideration of modality. Explain consequences clearly while preserving shared decision-making. Labeling the behavior alone does not identify the mechanism and can prevent a modifiable barrier from being addressed.
Apply it
A patient repeatedly misses the first weekly session after a transport service changes routes. Coordinate reliable transportation and discuss an alternative schedule with the team while reassessing fluid and electrolyte consequences of the missed treatments.
Common pitfall: Repeating risk education will not fix a transport failure. Respecting autonomy also does not require ignoring depression, misunderstanding or treatable symptoms that are influencing decisions.
52.Which practical capabilities matter when considering home hemodialysis?
Home hemodialysis selection combines clinical suitability with training capacity, the home environment, equipment requirements and available support. Patients need a clear understanding of access care, treatment tasks and how to respond to alarms or problems. Home schedules can offer flexibility but introduce responsibilities that differ from in-center care. Assess whether barriers can be addressed through training or assistance. Emergency and backup arrangements are part of preparation rather than an optional addition after treatment begins.
Apply it
A patient wants home hemodialysis to accommodate work but is anxious about alarms. Arrange program assessment and structured training, including response and backup plans, before deciding whether anxiety reflects a manageable learning need or a persistent practical barrier.
Common pitfall: Enthusiasm alone does not establish readiness, but lack of prior technical experience does not establish inability. Evaluate skills after appropriate education rather than relying on assumptions.
53.Why can rapid initial dialysis cause neurologic deterioration?
Dialysis disequilibrium involves osmotic shifts that can occur when blood solutes fall faster than equilibration with the brain, particularly during initial treatment of marked azotemia. Headache, nausea or altered mental status during treatment requires assessment rather than automatic attribution to ordinary fatigue. Initial prescriptions may limit rapid solute change in patients at risk. Other causes, including hypotension, glucose abnormalities, stroke and infection, must remain in the differential because neurologic deterioration is not specific to disequilibrium.
Apply it
A markedly azotemic patient develops headache and confusion during an initial dialysis treatment. Escalate clinical assessment and review the treatment prescription while evaluating blood pressure, glucose and other neurologic causes instead of assuming the symptoms are routine adjustment.
Common pitfall: Not every postdialysis headache is disequilibrium, and severe neurologic symptoms need urgent evaluation. Aggressive initial solute removal is not automatically safer because laboratory values improve faster.
54.How do peritoneal dialysis exchanges remove solute and fluid?
Peritoneal dialysis places prescribed solution in the abdomen so the peritoneal membrane permits solute movement and osmotic water removal. Each exchange includes filling, dwelling and draining. Automated PD uses a cycler, often overnight, while manual exchanges provide another treatment approach and an important contingency skill. Effectiveness depends on the prescribed solution, dwell pattern and completed exchanges. Mechanical or supply problems require a backup plan rather than assuming the machine is the entire treatment.
Apply it
A cycler-dependent patient faces a power outage. Use the program's trained manual-exchange contingency and contact pathway, with prescribed supplies and technique, instead of improvising a different solution or simply assuming every exchange must be omitted overnight.
Common pitfall: APD and manual PD use the same general peritoneal principle but have different workflows. Backup exchanges require prior training and a prescribed plan, not untrained improvisation.
55.Which findings establish peritoneal dialysis peritonitis?
ISPD diagnoses peritonitis when at least two of three criteria are present: compatible symptoms such as abdominal pain or cloudy effluent; effluent leukocytes above 100/µL after a dwell of at least two hours with more than 50% neutrophils; or a positive effluent culture. During rapid-cycle APD, more than 50% neutrophils provides strong evidence of peritonitis even when the absolute leukocyte count is below 100/µL. Interpret this with clinical findings. Cloudy effluent should prompt urgent specimen collection and treatment for suspected disease.
Apply it
An APD patient has abdominal pain and cloudy effluent after short dwells. The leukocyte count is 85/µL with 80% neutrophils. The short dwell makes the differential particularly important and supports urgent evaluation for peritonitis despite the lower absolute count.
Common pitfall: A rigid leukocyte cutoff can miss APD peritonitis after short dwells. A negative initial culture also does not exclude disease when the other diagnostic criteria are met.
ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment
56.How should empirical antibiotics and antifungal prophylaxis be selected for a PD patient?
Collect effluent for cell count, differential and culture, then promptly start empirical antibiotics covering gram-positive and gram-negative organisms. ISPD-supported choices include cefazolin or vancomycin for gram-positive coverage plus ceftazidime or an aminoglycoside for gram-negative coverage. Local susceptibility patterns, prior organisms, allergies and patient factors guide selection; a high prevalence of methicillin resistance favors vancomycin over cefazolin. Consider ototoxicity and residual kidney function when assessing aminoglycoside use. Intraperitoneal delivery is generally preferred unless systemic sepsis or another circumstance requires systemic treatment. Subsequent cultures and response guide narrowing or changing therapy. ISPD recommends co-prescribing antifungal prophylaxis whenever a PD patient receives an antibiotic course, regardless of the antibiotic's indication, to reduce fungal peritonitis. Oral nystatin or fluconazole can be selected according to availability, interactions and patient factors; review the medication list carefully before selecting fluconazole.
Apply it
A stable PD patient has cloudy effluent and abdominal pain. After specimens are collected, intraperitoneal cefazolin plus ceftazidime is a reasonable empirical combination where local susceptibility supports it and no relevant allergy is present. If local methicillin resistance is high, vancomycin plus ceftazidime may better fit initial coverage needs. Co-prescribe antifungal prophylaxis: oral nystatin is an option when available and suitable; fluconazole is an alternative after assessing interactions and patient factors. The prophylaxis recommendation also applies if this patient later receives an antibiotic course for a nonperitoneal infection.
Common pitfall: Do not wait for organism identification or assume cefazolin alone provides adequate empirical coverage. Route and dose must fit the PD regimen and dwell schedule; systemic sepsis requires immediate assessment beyond routine outpatient intraperitoneal treatment. Antifungal prophylaxis accompanies the antibiotic course and does not replace antibacterial treatment; its indication is not limited to antibiotics prescribed for peritonitis.
ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment
57.Why must anti-rejection treatment continue when a transplant functions well?
A functioning transplant remains immunologically different from the recipient, so good laboratory results do not remove rejection risk. Continued prescribed immunosuppression and laboratory monitoring are necessary, often for the life of the graft. Medication reconciliation must include interactions, access to refills and any missed doses. Infection prevention and side-effect management support adherence. Patients should contact the transplant team before changing treatment because independently stopping or reducing medication can threaten an otherwise well-functioning graft.
Apply it
A recipient feels well and wants to stop anti-rejection medication because creatinine is normal. Explain that normal function reflects successful ongoing management, assess side effects or cost barriers, and coordinate any changes with the transplant team.
Common pitfall: Absence of symptoms does not demonstrate immune tolerance. Generic advice to take medicines is inadequate when refill access, adverse effects or misunderstanding are driving missed doses.
58.How should persistent unexplained allograft dysfunction be evaluated?
A sustained creatinine rise after transplantation can reflect dehydration, obstruction, medication toxicity, infection, rejection or recurrent disease. Evaluate reversible contributors and relevant medication levels and imaging rather than assuming one cause. KDIGO recommends allograft biopsy for a persistent unexplained creatinine increase. Tissue assessment can distinguish processes requiring very different treatments. A drug concentration within its intended range does not exclude rejection, and empirically changing immunosuppression without adequate evaluation may worsen an unrecognized alternative diagnosis.
Apply it
A recipient has a persistent creatinine rise despite correction of dehydration, unobstructed imaging and an appropriate immunosuppressant level. Coordinate transplant evaluation for biopsy rather than accepting the level as proof that rejection cannot be present.
Common pitfall: Creatinine identifies dysfunction, not its mechanism. Treating every rise as rejection or every rise as calcineurin toxicity can expose the graft to the wrong intervention.
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
59.Why is skin cancer prevention part of transplant follow-up?
Chronic immunosuppression increases skin cancer risk, making prevention and early recognition integral to transplant care. KDIGO recommends counseling about ultraviolet protection, minimizing sun exposure and performing skin self-examination, with regular professional assessment. Patients should report new or changing lesions rather than waiting for routine visits when concerned. Education should be practical, covering protective clothing and sunscreen use. Reducing cancer risk requires coordinated surveillance, not independently stopping the immunosuppression that protects the graft.
Apply it
A long-term transplant recipient notices a growing scaly lesion but plans to wait until next year's review. Arrange timely assessment and reinforce skin surveillance and sun protection while continuing prescribed anti-rejection treatment pending transplant-team advice.
Common pitfall: A lesion's small size or lack of pain does not establish benignity. Advising independent immunosuppression withdrawal substitutes rejection risk for a problem requiring proper evaluation.
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
60.When can continuous KRT be preferable in acute illness?
Continuous KRT spreads fluid and solute removal over time, which can improve tolerability when acute kidney injury occurs with hemodynamic instability. KDIGO suggests CRRT rather than standard intermittent therapy for hemodynamically unstable patients. Modality choice also considers cerebral edema risk, resources and clinical goals. Starting acute KRT depends on the overall clinical context, especially life-threatening fluid, electrolyte or acid-base disturbances, rather than an isolated creatinine or urea threshold. Continuous treatment does not guarantee recovery or survival benefit.
Apply it
A vasopressor-dependent patient with AKI develops refractory pulmonary edema and cannot tolerate rapid fluid shifts. Continuous KRT is a reasonable modality to discuss for gradual removal while treating the underlying shock and monitoring the evolving clinical condition.
Common pitfall: A high creatinine alone does not mandate CRRT. Hemodynamic tolerance is a reason to select a modality, not proof that continuous therapy universally improves survival.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Give KRT the largest study allocation, especially hemodialysis volume assessment, vascular access, infection prevention and delivered treatment.
- Connect each assessment cue to an NP decision: investigate, prescribe, monitor, educate or coordinate care.
- Distinguish stable CKD preparation from symptom-driven dialysis initiation and emergency KRT indications.
- Work prescribing cases using SGLT2 initiation and withholding criteria, iron initiation and withholding criteria, drug-specific ESA instructions, alkali monitoring, levetiracetam dialysis supplements and empirical PD antibiotics with antifungal prophylaxis.
- Distinguish cardiac protection, temporary intracellular potassium shifting and potassium removal in acute hyperkalemia; reassess potassium and glucose after treatment.
- Use serial patterns and clinical context rather than isolated creatinine, PTH, ferritin, blood pressure or access measurements.
- Include PD, transplantation and CRRT while recognizing their smaller subdivisions within the linked KRT blueprint.
- Use the complete official outline to identify topics beyond this selective guide, including unfamiliar settings and procedures.
A practical preparation plan
1. Map practice experience to the outline
Review all five domains and the NP activity axis. Identify settings you rarely encounter, such as advanced nondialysis CKD, PD, transplantation or acute KRT. Allocate most study time to KRT while reserving deliberate coverage for every domain.
2. Build mechanism-to-decision explanations
For each concept, explain the mechanism aloud, identify the decisive clinical cue and name the tempting alternative. Rework the mini-case after changing one finding, such as volume status, albuminuria, dwell time or the persistence of an abnormal result.
3. Practise quantitative and prescribing decisions
Calculate creatinine ratios, percentage changes and specified ultrafiltration rates. Apply ferritin and TSAT criteria, distinguish daily doses from dialysis supplements, and compare agent-specific withholding intervals. State units and assumptions, then connect each result to the clinical decision.
4. Complete and review the question set
Answer the 20 independent questions before reading explanations. Review why each alternative is less appropriate and classify errors as missing knowledge, missed cues or incorrect application. Revisit the corresponding clinical source and concept.
5. Use recall and close coverage gaps
Space flashcard review over several sessions and answer before revealing the back. Finish by checking the full NNCC outline and applicable candidate information, especially the conflicting blueprint versions, rather than treating completion of this guide as exhaustive preparation.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- CNN-NP | Nephrology Nursing Certification Commission
- Ideal Distribution of Questions in CNN-NP Certification Examination
- CNN-NP Examination Specifications (Blueprint)
- CNN-NP Certification Preparation Guide
- CNN-NP Certification Examination Application, revised January 2025
- KDIGO Clinical Practice Guideline for Acute Kidney Injury
- Identify & Evaluate Patients with Chronic Kidney Disease
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease
- KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
- KDIGO 2017 CKD-MBD Guideline Update
- KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease
- Conservative Management for Kidney Failure
- Choosing a Treatment for Kidney Failure
- Blood pressure and volume management in dialysis: KDIGO Controversies Conference conclusions
- KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update
- Hemodialysis
- Infections and Patients on Dialysis
- Best Practices for Bloodstream Infection Prevention in Dialysis Setting
- CDC Pink Book, Chapter 10: Hepatitis B
- International Society for Peritoneal Dialysis Guidelines
- ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment
- Peritoneal Dialysis
- KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
- Kidney Transplant
- Eating & Nutrition for Hemodialysis
- Getting More Protein While on Dialysis
- DailyMed - JARDIANCE- empagliflozin tablet, film coated
- DailyMed - STEGLATRO- ertugliflozin tablet, film coated
- DailyMed - EPOGEN- epoetin alfa solution
- DailyMed - KEPPRA- levetiracetam tablet, film coated KEPPRA- levetiracetam solution
- KDIGO-Acute-Hyperkalemia-conf-report-FINAL.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.